Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun;125(6):365-367.
doi: 10.1055/s-0042-123710. Epub 2017 Feb 6.

Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients

Julia D J Thomas  1 , Abhishek Dattani  1   2 , Filip Zemrak  2 , Thomas Burchell  2 , Scott A Akker  3 , Felicity J L Kaplan  4 , Bernard Khoo  5 , Simon Aylwin  6 , Ashley B Grossman  7 , L Ceri Davies  2 , Márta Korbonits  1
Affiliations
Clinical Trial

Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients

Julia D J Thomas et al. Exp Clin Endocrinol Diabetes. 2017 Jun.

Abstract

Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure. Acromegaly is associated with a disease-specific cardiomyopathy, the pathogenesis of which is poorly understood.The cardiac indices of patients with active acromegaly with no hypertension (Group A, n=4), established hypertension not taking ACEi/ARBs (Group B, n=4) and established hypertension taking ACEi/ARBs (Group C, n=4) were compared using cardiac magnetic imaging.Patients taking ACEi/ARBs had lower end diastolic volume index (EDVi) and end systolic volume index (ESVi) than the other 2 groups ([C] 73.24 vs. [A] 97.92 vs. [B] 101.03 ml/m2, ANOVA p=0.034, B vs. C p<0.01). Groups A and B had EDVi and ESVi values at the top of published reference range values; Group C had values in the middle of the range.Acromegaly patients on ACEi/ARBs for hypertension demonstrate improved cardiac indices compared to acromegaly patients with hypertension not taking these medications. Further studies are needed to determine if these drugs have a beneficial cardiac effect in acromegaly in the absence of demonstrable hypertension.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None.

Figures

Fig. 1
Fig. 1
Graph comparing EDVi and ESVi in the 3 groups. There is a significant difference (p<0.01) between Group B and Group C. Error bars indicate SEM.
See this image and copyright information in PMC

References

    1. Suzuki H, Kusuyama T, Omori Y et al. Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction. Int Heart J. 2006;47:715–725. - PubMed
    1. Bazzino O, Navarro Estrada J L, Sosa Liprandi A et al. Early treatment with low-dose enalapril after acute myocardial infarction: an equilibrium radionuclide angiographic study. Enalapril despues del Infarto (EDI) Trial Investigators. J Nucl Cardiol. 1997;4:133–139. - PubMed
    1. Greenberg B, Quinones M A, Koilpillai C et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573–2581. - PubMed
    1. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555–573. - PubMed
    1. Colao A, Marzullo P, Di Somma C et al. Growth hormone and the heart. Clin Endocrinol. 2001;54:137–154. - PubMed

Substances